Pulmocide Ltd.
- Country
- ๐ฌ๐งUnited Kingdom
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.pulmocide.com
Clinical Trials
16
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)โข Click on a phase to view related trials
Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Pulmocide Ltd
- Target Recruit Count
- 123
- Registration Number
- NCT05238116
- Locations
- ๐ฌ๐ง
Clinical Research Site, Manchester, United Kingdom
๐บ๐ธClinical R Site, Los Angeles, California, United States
๐ฎ๐ณClinical Research Site 1, Pune, Maharashtra, India
A Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)
- Conditions
- Pulmonary Aspergillosis
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Pulmocide Ltd
- Target Recruit Count
- 102
- Registration Number
- NCT05037851
- Locations
- ๐จ๐ฆ
Clinical Research Site, Toronto, Canada
๐บ๐ธResearch Site, Saint Louis, Missouri, United States
๐บ๐ธClinical Research Site 1, Houston, Texas, United States
The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.
- Conditions
- Lung Transplant InfectionAspergillosis
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Pulmocide Ltd
- Target Recruit Count
- 2
- Registration Number
- NCT03905447
- Locations
- ๐ฌ๐ง
Papworth Hospital, Papworth Everard, Cambridge, United Kingdom
๐ฌ๐งHarefield Hospital, Harefield, Uxbridge, United Kingdom
๐ฌ๐งWythenshawe Hospital, Manchester, United Kingdom
The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Pulmocide Ltd
- Target Recruit Count
- 4
- Registration Number
- NCT03870841
- Locations
- ๐ฌ๐ง
Royal Brompton Hospital, London, United Kingdom
๐ฌ๐งNorthwest Lung Research Centre, Manchester, United Kingdom
The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases
- Conditions
- AsthmaRespiratory AspergillosisCOPDBronchiectasisRespiratory Candidiasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- Pulmocide Ltd
- Target Recruit Count
- 13
- Registration Number
- NCT03745196
- Locations
- ๐ฌ๐ง
Glenfield Hospital, Leicester, United Kingdom
๐ฌ๐งRoyal Liverpool University Hospital, Liverpool, United Kingdom
๐ฌ๐งRoyal Brompton Hospital, London, United Kingdom
- Prev
- 1
- 2
- Next